Indian Drug Maker Procures Two Patents for Neurodegenerative Drug

Indian biopharmaceutical company, Suven Life Sciences has secured two patents from two different countries on its new chemical entities (NCE's) for the treatment of several neurodegenerative diseases.

The company has received one patent from Australia and another from Canada. Both are valid through 2032 and 2031 respectively.

''The granted claims of the patent from Australia include the class of selective 5-HT4 compounds and the granted claims of the patent from Canada is through mechanism of action - H3 Inverse agonist and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia,'' the company stated.

‘Suven Life Sciences secures two patents for its therapeutic agents useful in the treatment of cognitive impairment associated with neurodegenerative disorders.’

Suven Life CEO Venkat Jasti said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally."

Source: Medindia

Three New Product Patents for Suven Life Sciences

Suven Life Sciences haas secured three product patents which are useful for treating neurodegenerative disorders.

Suven Life Sciences Starts Phase I Trial for Alzheimer’s Drug

Hyderabad-based Suven Life Sciences announced that it has started Phase I clinical trial of its experimental drug.

Indian Biotech Company to File A Global Patent for Zika Vaccine

Bharat Biotech is probably the first in the world to file a "global patent" for its vaccines against the Zika virus that is suspected to cause birth defects.

US Researchers Patent Low-Cost Printer To Track Health Of HIV Patients

The portable device assist clinicians to count the number of CD4 cells and help doctors and patients in low-resource settings who do not have access to flow cytometers.